ClinicalTrials.gg
RecruitingNCT06063005Updated Oct 30, 2023

Clinical Study of Translocated Internal Limiting Membrane Flap Reposition for the Treatment of Idiopathic Macular Hole

An interventional study of Translocation ILM Flap and ILM Peeling in Macular Holes, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 55 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2022, registered Sep 2023).
  • Started Jul 2022; still recruiting 4 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
55 Years to 70 Years
Sex
All
01

Study summary

The main objective of this study is to evaluate the therapeutic effectiveness of the internal limiting membrane (ILM) peeling and translocation surgery compared to the conventional surgical approach for treating large idiopathic macular hole (IMH) through a well-designed prospective randomized controlled clinical trial. This study aims to compare the new surgical approach to the conventional approach in terms of improving visual function, promoting macular retinal anatomical healing, and enhancing patients' quality of life. By conducting this prospective clinical trial, establishing a database, and generating clinical reports and evidence-based medicine on the therapeutic efficacy of the ILM peeling and translocation surgery for large IMH.

02

Conditions studied

  • Macular Holes

Browse trials for

03

In context

Retinal Perforations

139 studies on the registry are indexed under Retinal Perforations; 22 are open to participants now.

This study's planned enrollment of 76 is above the median of 50 across 94 interventional studies indexed under Retinal Perforations.

Browse Retinal Perforations studies →

Lead sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who can understand the purpose of this clinical trial, volunteer to participate, sign an form, and can complete the postoperative follow-up on time.
  • Participants diagnosed with idiopathic macular hole (IMH).
  • Based on OCT scans, the minimum horizontal diameter of the macular hole is >500 and \<900 µm.
  • Participants with an axial length \<26.0mm and a myopic degree lower than 6D.
  • For participants with bilateral macular holes, the eye with a larger hole diameter will be included.

Exclusion criteria

Exclusion Criteria:

  • Patients with the following retinal disorders: age-related macular degeneration, epi-macular membrane neovascularization, non-macular retinal tears, lesions of the retinal pigment epithelium and choroid, inherited or degenerative retinal diseases, optic neuropathies, retinal vascular diseases; patients with large macular holes accompanied by retinal detachment;
  • Patients with high myopia (axial length ≥ 26.0mm and myopia exceeding 6D);
  • Patients with a history of ocular trauma or retinal laser treatment;
  • Patients with glaucoma, ocular infections, inflammations, tumors, corneal diseases, or amblyopia;
  • Patients with to vitrectomy;
  • Patients with severe or unstable systemic diseases;
  • Patients with a fasting blood glucose level ≥ 9mmol/L before surgery;
  • Patients who participated in other clinical trials involving drugs or medical devices within 30 days prior to screening;
  • Patients with a history of intraocular surgery within 3 months prior to screening;
  • Patients with reduced visual function or vision in the contralateral eye as determined by the investigator;
  • Patients who are not considered suitable for enrollment by the investigator for other reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Translocation

    Procedure: Translocation ILM Flap

  • Active comparator
    Peeling

    Procedure: ILM Peeling

Interventions

  • ProcedureTranslocation ILM Flap

    After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.

  • ProcedureILM Peeling

    After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    The best corrected visual acuity indicates the best visual acuity with proper refractive correction.

    Time frame: 1 week, 1 month, 3 months, 1 years, 2 years after the operation

Secondary outcomes

  1. Closure rate

    MH closure is mainly reflected in the outer layer of continuity closure shown on OCT.

    Time frame: 1 week, 1 month, 3 months, 1 years, 2 years after the operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for May 2025, 34 months after the start.

Of 45 non-industry interventional studies with no phase under Retinal Perforations, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 34 months is above that.

Counting every sponsor, half of 45 studies reached it within 28 months; a quarter within 12 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 2, 2023
StartActual
Jul 1, 2022
Primary completionEst.
May 1, 2025
CompletionEst.
Jun 30, 2025
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063005
Collaborators
Shanghai Municipal Science and Technology Commission
Responsible party
Peiquan Zhao (Professor, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Oct 2, 2023
Start date
Jul 1, 2022
Primary completion
May 1, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Oct 30, 2023

Study contacts

Peiquan Zhao, Dr.
Contact
zhaopeiquan@xinhuamed.com.cn
0086 13311620396
Jiao Lyu, Dr.
Contact
cherryfcl@126.com
0086 13564910954
Peiquan Zhao, Dr.
study chair · Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion